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NUBPL (Nucleotide-binding protein like) protein encodes a member of the Mrp/NBP35 ATP-
binding proteins family, deemed to be involved in mammalian complex I (CI) assembly 
process. Exome sequencing of a patient presenting with infantile-onset hepatopathy, renal 
tubular acidosis, developmental delay, short stature, leukoencephalopathy with minimal 
cerebellar involvement and multiple OXPHOS deficiencies revealed the presence of two novel 
pathogenic compound heterozygous variants in NUBPL (p.Phe242Leu/p.Leu104Pro). We 
investigated patient’s and control immortalized fibroblasts and demonstrated that both the 
peripheral and the membrane arms of complex I are undetectable in mutant NUBPL cells, 
resulting in virtually absent CI holocomplex and loss of enzyme activity. In addition, complex 
III stability was moderately affected as well. Lentiviral-mediated expression of the wild-type 
NUBPL cDNA rescued both CI and CIII assembly defects, confirming the pathogenicity of the 
variants. In conclusion, this is the first report describing a complex multisystemic disorder due 
to NUBPL defect. In addition, we confirmed the role of NUBPL in Complex I assembly 
associated with secondary effect on Complex III stability and we demonstrated a defect of 
mtDNA-related translation which suggests a potential additional role of NUBPL in mtDNA 
expression. 
 
Key words: Mitochondrial disorders, NUBPL, human complex I, complex I assembly, 
complex I assembly factors, brain MRI. 
  
Introduction 
The primary function of mitochondria is to provide energy to the cells. This role is carried out 
by the oxidative phosphorylation (OXPHOS) pathway, composed of five multi-subunit 
complexes and two mobile electron carriers (ubiquinone and cytochrome c), embedded in the 
inner mitochondrial membrane (IMM). Complexes I to IV carry out respiration, i.e. the 
transport of electrons extracted from nutrients to molecular oxygen, that sustains the generation 
of a proton gradient across the membrane, exploited by complex V to phosphorylate ADP, 
converting it into ATP. Human complex I (CI) is an initial step of the electron transport chain. 
It is composed of 45 different subunits (Vinothkumar, Zhu, & Hirst, 2014) organized in three 
structural domains: a membrane arm, or P module, and two peripheral domains, the N and the 
Q modules, protruding in the mitochondrial matrix. In the N module, Nicotinamide 
Dehydrogenase (NADH) is oxidised by flavin mononucleotide (FMN) and electrons are passed 
through a chain of 8 iron-sulfur (Fe-S) clusters, and eventually transferred to ubiquinone, 
bound to the Q module. For every oxidised NADH molecule, the P-module pumps four protons 
across the inner membrane from the matrix to the intermembrane space of mitochondria, 
contributing to the formation of the protonmotive force (Birrell, Morina, Bridges, Friedrich, & 
Hirst, 2013; Mimaki, Wang, McKenzie, Thorburn, & Ryan, 2012). Isolated mitochondrial CI 
deficiency (MIM# 252010), due to pathogenic variants in CI subunits or assembly factors, 
causes severe decrease of energy production and is the most common cause of OXPHOS 
disorders (Nouws, Nijtmans, Smeitink, & Vogel, 2012). Nucleotide-binding protein like 
(NUBPL) (MIM# 613621) encodes a member of the Mrp/NBP35 ATP-binding proteins family 
(Bych et al., 2008; Sheftel et al., 2009). Similar to cytosolic members of this protein family, 
e.g. Cfd1 and Nbp35, NUBPL is able to bind Fe-S clusters thanks to the presence of two highly 
conserved cysteine residues in a CxxC motif in the C-terminal domain of the protein, but the 
precise molecular mechanism remains unclear (Sheftel et al., 2009). NUBPL defect causes a 
leukoencephalopathy with a distinct brain MRI pattern predominantly involving cerebellar 
cortex, deep white matter and corpus callosum at early stage and progressing to severe 
cerebellar atrophy and brainstem involvement at the late stage (Kevelam et al., 2013). 
Currently, 10 patients with NUBPL pathogenic variants are reported in the literature (Balint et 
al., 2019; Calvo et al., 2010; Kevelam et al., 2013; Tenisch et al., 2012; Tucker et al., 2012) 
presenting a neurodevelopmental disorder with mild to severe ataxia, dystonia, spasticity and 
dysarthria (Table I-Figure1). Here, we report for the first time a complex multisystemic 
syndrome due to novel compound heterozygous pathogenic variants in NUBPL in a 13-year-
old girl. Functional analyses were previously limited to the determination of CI enzymatic 
activity and steady-state levels in human defective NUBPL samples. In this study, we have 
performed an extensive biochemical, genetic and protein analysis of our patient-derived 
fibroblast cell line harbouring compound heterozygous NUBPL pathogenic single nucleotide 
variants bringing new insights into the disease mechanism of NUBPL. 
 
Case Report 
A 13-year-old girl, the first child of healthy unrelated parents, was born at term after uneventful 
pregnancy and normal delivery. Birth weight was 3,330 g. Perinatal period was normal 
(APGAR score 8/10). At age 18 months, she presented with failure to thrive (HP:0001508) and 
developmental delay (HP:0001263). At age 30 months, a type III renal tubular acidosis 
(HP:0001947) was identified. Laboratory investigations showed increased levels of lactate in 
plasma and in urine. 
At this age neurological assessment documented generalized hypotonia (HP:0001290), wasting 
and weakness with positive Gowers sign (HP:0003198). Brain MRI revealed an asymmetric 
leukoencephalopathy (HP:0002352) with predominant fronto-parietal involvement, swelling 
of the corpus callosum and restricted diffusion at the edges of the affected white matter, 
associated with a small cortical cerebellar lesion (Figure 2A-E). Brain MR spectroscopy 
revealed lactate peaks at the level of both affected and normalappearing cerebral white matter 
(Figure 2K, L). 
At 6 years, mild hepatomegaly (HP:0002240), short stature (HP:0004322) and severe 
osteoporosis (HP:0000939) were noted. Endocrinological evaluation detected a complete 
growth hormone deficiency (HP:0000824) and replacement treatment was started. At 7 years 
of age, pulmonary CT scan revealed interstitial lung disease (HP:0006530). Sweat test was 
negative. At this time, the child showed generalized muscle hypotrophy, hyposthenia and signs 
of peripheral reduced oxygenation with nail clubbing. Follow-up brain MRI showed 
improvement of the cerebral white matter abnormalities, with decrease in both white matter 
swelling and extent of the signal abnormalities, whereas the cerebellar abnormalities had 
slightly worsened (Figure 2F-J). Brain MR spectroscopy demonstrated absence of lactate peaks 
in the affected white matter (Figure 2M). Cardiac (including ECG and echocardiography), 
funduscopy, and hearing assessments were normal. Over the following years the clinical course 
remained stable with satisfactory electrolyte balance and metabolic compensation and stability 
of motor functions. At 12 years of age she presented a critical episode characterized by 
hypertonia to the limbs with loss of contact and tachypnea. EEG showed significant slowing 
in right frontal seat. 
Laboratory results indicated the presence of increased plasma levels of alanine, lactic and 
butyric acid. A muscle biopsy performed at 36 months revealed an irregular pattern of 
Cytochrome C Oxidase (COX) activity. In addition, mitochondrial respiratory chain activities 
measured in muscle homogenate showed a significant reduction in CI+III (NADH-Cytochrome 
C reductase) and a marginal reduction in CII+III (Succinate cytochrome c reductase) (Table 
II). At her last examination, at 13 years of age, she complained of easy fatigability and she 




Exome sequencing of patient’s blood DNA identified two pathogenic variants in NUBPL 
(NM_025152.3; NP_079428.2; #MIM 613621): c.726C>G, p.Phe242Leu, in exon 9, not 
previously reported; c.311T>C, p.Leu104Pro, in exon 4, previously reported in compound 
heterozygosity with another pathogenic variant. Sanger’s sequencing in the parents, proved 
that the pathogenic variants were allelic, the c.726C>G being transmitted by the heterozygous 
father and the c.311T>C by the heterozygous mother. Both parents are heathy carrier. The two 
pathogenic variants are localized in two different functional domains of the protein, and are 
both highly conserved in different species. ClustalW alignment of NUBPL and the human 
orthologues of cytosolic Fe/S proteins Cfd1/Nbp35  (NUBP1/NUBP2) (Figure S1) shows that 
the first pathogenic variant (p.Leu104Pro) localizes in the Walker B motif, essential for 
nucleotide binding and hydrolysis (Leipe, Koonin, & Aravind, 2003). The second pathogenic 
variant (p.Phe242Leu) is in close proximity to the CxxC binding residues and may affect the 
ability of the protein to bind the Fe-S clusters or to form homodimers (Netz et al., 2012). 




We first analyzed the steady-state levels of respiratory chain subunits, particularly those 
forming the different CI submodules in immortalized patient-derived skin fibroblasts (Signes 
& Fernandez-Vizarra, 2018). SDS-PAGE based Western blot (WB) immunodetection showed 
strong reduction of the steady-state level of CI subunits localized in both the peripheral and 
membrane arms, suggesting a deleterious effect of the NUBPL pathogenic variants on the 
whole enzyme (Figure 3A-S2). Steady-state levels of subunits of other respiratory chain 
complexes (Figure 3A) and of Aconitase 2 (ACO2) (Figure 4A), a mitochondrial matrix protein 
containing a 4Fe-4S cluster involved in the conversion of Citrate to Isocitrate, did not show 
abnormalities. Likewise, the amount of the Fe-S containing structural components of CIII 
(UQCRFS1) was not affected. 1st and 2nd dimension (1D and 2D) BN-PAGE analysis of DDM-
treated samples demonstrated a dramatic reduction of the fully assembled CI in patient’s 
fibroblasts, whereas both CIII and CII, as well as CIV, holocomplexes were normal (Figures 
3B and 3C). These results confirm the high specificity of NUBPL for the assembly/stability of 
CI subunits. 
In order to study the effect of the two pathogenic variants in the formation of supercomplexes 
(SC), we analyzed mitochondria extracted from fibroblasts treated with 1% digitonin by 1D 
and 2D BN-PAGE WB (Figures 3D and 3E). This analysis showed a marked reorganization of 
the SC in the patient, including the loss of the respirasome (CI+CIII2+CIV), with the 
maintenance of the CIII2+CIV species. However, WB analysis of 2D BN using UQCRFS1, the 
only CIII subunit containing an iron-sulfur cluster, and UQCRC1, a CIII core subunit, showed 
accumulation of CIII sub-assemblies in the patient’s cells (Figure 3E). Interestingly, similar 
results, although less drastic, were obtained from the analysis of another human cell line 
defective for the complex I assembly factor ACAD9, including the decrease in the amount of 
SC (Figure S3). (Garone et al., 2013) Besides Complex I assembly, NUBPL has been deemed 
to play a role in mitochondrial translation in Arabidopsis thaliana (Wydro et al., 2013). We 
analyzed mitochondrial translation by [35S]-L-methionine metabolic labelling, and found that 
the amount of mtDNA-related subunits was moderately decreased in mutant fibroblasts 
compared to controls (Figure 3F-S4), and also to the ACAD9 defective fibroblasts (Figure S5). 
Spectrophotometric analysis of the respiratory chain complexes confirmed severe CI 
deficiency with 22% residual activity of patient’s vs controls’ fibroblasts (Figure 3G), whereas 
the activities of the other complexes, including those containing mtDNA encoded subunits, 
were normal. These results indicate again the specificity of the NUBPL defect on CI function, 
and suggest that the mild reduction in mtDNA translation is unlikely to affect the function of 
the remaining complexes. 
 
Functional complementation assay 
To further confirm the pathogenicity of the pathogenic variants, we performed 
complementation experiments by overexpressing NUBPL wild-type cDNA in patient’s and 
control fibroblasts by stable lentivirus transduction. The overexpression of the native protein 
fully restored the steady-state whole CI amount, assembly and enzyme activity and the 
correction of the mtDNA translation defect in the patient’s cells (Figure 4A-F; Figure S6-7). 
 
Discussion 
NUBPL defect cause leukoencephalopathy with early onset (0-24m) of developmental delay 
or motor regression and mild to severe ataxia, spasticity, dystonia, dysarthria and myopathy. 
Currently, 10 patients have been reported with variable disease course: four patients presented 
episodes of regression, two patients a progressive disease course; three had a stable disease 
course with acquisition of some milestones. Here, we describe for the first time a progressive 
multisystem clinical phenotype with type III renal tubular acidosis, osteoporosis, 
hepatomegaly, growth hormone deficiency, interstitial lung disease. Brain MRI confirmed the 
association of leukoencephalopathy with cerebellar, corpus callosum and deep cortical 
involvement. However, neurological features were not the most predominantly debilitating 
symptoms and they were including myopathy, hypotonia and neurocognitive deficit. NUBPL 
defect in our patient was due to compound heterozygous pathogenic variants: one very recently 
described variant in a different compound heterozygosity (c.311T>C, p.Leu104Pro) (Balint et 
al., 2019) and a novel unreported variant (c.726C>G, p.Phe242Leu). While the first pathogenic 
variant is localized in a Walker B motif essential for nucleotide bind, the second pathogenic 
variant is localized in proximity to the CxxC binding residues to the Fe-S clusters. Therefore, 
we can hypothesize a genotype-phenotype correlation with the c.726C>G, p.Phe242Le 
pathogenic variant responsible of the most severe and complex phenotype of our patient. 
Further studies with additional identified patients are needed to confirmed our hypothesize. 
NUBPL has been identified as a CI assembly factor, involved in the insertion of 4Fe-4S clusters 
in the CI N module (Sheftel et al., 2009). and in two 4Fe-S metallated subunits of the Q module, 
NDUFS2 and NDUFS3 (Sanchez-Caballero, Guerrero-Castillo, & Nijtmans, 2016; Sheftel et 
al., 2009). We have performed an extensive functional analysis of our patient fibroblast cell 
line and we have demonstrated that NUBPL defect compromises the assembly of the whole 
CI. The assembly pathway of CI has recently been described as a modular process, which 
requires the synthesis of six independent multiprotein sub-modules (Q, PP-a, PP-b, PD-a, PD-b, 
N), subsequently integrated to form the holoenzyme via a stepwise process involving at least 
13 assembly factors and chaperons (Guerrero-Castillo et al., 2017). Both the N and the Q 
modules are pre-assembled before their incorporation in the holoenzyme. However, whilst the 
Q module is added to the membrane arm at an early stage, the insertion of the N module is one 
of the final steps of the complete assembly of CI (Guerrero-Castillo et al., 2017; Sanchez-
Caballero et al., 2016). Previous structural analysis of CI by blue native gel electrophoresis in 
patients’ cells with pathogenic variants in N and Q module subunits has shown the 
accumulation of stable CI intermediates corresponding to the unconnected N module and to 
the incomplete membrane arm, which can contain also Q module subunits, such as NDUFA9 
and NDUFS2 (Lazarou, McKenzie, Ohtake, Thorburn, & Ryan, 2007). Therefore, pathogenic 
variants causing the destabilization of either the N or the Q modules are not sufficient to 
determine the complete loss of the enzyme. Contrariwise, our results demonstrate a drastic 
effect on CI impaired NUBPL activity, leading to a decrease of CI subunits belonging to all 
three modules and a general loss of the fully assembled complex. This observation suggests 
that NUBPL is involved in the formation of both the peripheral and membrane arms of the 
enzyme. The analysis of mitochondrial complexes extracted with digitonin in 1D and 2D blue 
native gels allowed us to investigate the formation and the stability of supercomplexes in our 
patient cell line. As expected, in the absence of CI there is a redistribution of the remaining 
complexes, which leads to an increase in CIII2 and CIII2+CIV species, while monomer CIV 
does not seem to be affected. Interestingly, NUBPL defective cell line showed also reduced 
stability or impaired assembly of CIII. The formation of SC seems to be important for the 
structural stabilization of the individual enzymes (Moreno-Lastres et al., 2012). A current 
standard model suggests that partially assembled CIII2 is incorporated in CI+CIII2+CIV SC, 
before the insertion of the Rieske protein (UQCRFS1), which is preferentially localized in SC 
rather than in free CIII2 [30]. This hypothesis is supported by the partial de-stabilization and 
degradation of CIII2 in our mutant cells, shown by 2D BN WB. 
We also observed a moderate defect in mitochondrial protein synthesis rate in the patient cells 
analyzed by [35S]-methionine labelling. This mildly affects all the mitochondrial encoded 
proteins, partially supporting a previous hypothesis on a role of NUBPL in mitochondrial 
translation (Wydro et al., 2013). The defect in the mitochondrial translation can be also 
responsible of instability of Complex III. 
In conclusion, our results confirm the role of NUBPL in the assembly of CI and suggest an 
involvement of the protein in the stability of the whole enzyme. Further investigation is 
warranted to establish as whether this effect is due to a direct function of NUBPL on assembly 
of holo-CI, or to a severely disruptive structural consequence of impaired CI Fe-S metallation. 
 
Methods 
Editorial Policies and Ethical Considerations 
This study was approved by the ethics committee of the Childern’s Hospital Giannina Gaslini 
Institute, Genova (Italy) and it has been carried out in accordance with The Code of Ethics of 
the World Medical Association (Declaration of Helsinki). The patient’s parents signed an 
informed consent approved by the Ethics Committee of the Gaslini Institute (available upon 
request), on the treatment of the biological material obtained from the patient. 
None of the Authors has conflicts of interest concerning the present work. 
 
Cell Biology 
Human fibroblasts were grown in Dulbecco's Modified Eagle Medium (DMEM, Gibco 
#10569010), supplemented with 10% foetal bovine serum (Gibco #10270-106), 1% penicillin 
and streptomycin (Gibco #15070-063) and 50 μg/ml uridine. Fibroblasts were immortalised by 
lentiviral transduction using the pLOX-Ttag-iresTK vector (Tronolab, Addgene #12246). 
Cells were lysed in TG lysis buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 1mM EDTA, 1% 
Triton-X-100, 10% Glycerol, 1.5 mM MgCl2) and 1x protease inhibitor cocktail (Roche 
#05056489001). The protein amount was detected with DC protein assay kit (BioRad 
#5000111) and 20 μg of protein were loaded in SDS-PAGE Nu-PAGE 4-12% Bis-Tris gel 
(Invitrogen #NP0321). Proteins were transferred to a PVDF membrane (Immobilon-P 




Samples for Blue Native Gel Electrophoresis (BNGE) were prepared as described previously 
(Nijtmans, Henderson, & Holt, 2002; Wittig, Braun, & Schagger, 2006) with DDM or 
Digitonin in order to analyse the supercomplexes. Native samples were run through pre-cast 
NativePAGE 3%–12% Bis-Tris gels, while Novex NuPAGE 4%–12% Bis-Tris Gels (Life 
Technologies) were used for denaturing conditions. Proteins were blotted to a PVDF 
membrane (Immobilon-P #IPVH00010) at 300 mA for 1.5 hours in bicarbonate transfer buffer 
(0.318 mg/ml Na2CO3, 0.84 mg/ml NaHCO3). Samples were immunodetected using 
commercial specific antibodies. A detailed list can be found in Supp. Table 1. 
In order to analyse the mitochondrial respiraotyr chain activities, cells samples were snapfrozen 
in liquid nitrogen and homogenized in 10 mM phosphate buffer (pH 7.4). The 
spectrophotometric activity of CI, CII, CIII, CIV, and CS, was measured as described in 
Bugiani et al. (Bugiani et al., 2004). 
CI activity was measured by following the decrease of NADH absorbance at 340 nm. Proteins 
were incubated during 2 minutes at 30°C in a reaction mix containing 20 mM KP buffer pH 8, 
0.2 mM NADH, 1 mM sodium azide, 0.1% BSA in 1 mM EDTA pH=7.4. The reaction was 
initiated adding 50 μM CoQ, followed for 2 min, and then inhibited with 5 μM rotenone. CII 
activity was performed at 30°C pre incubating proteins with 50 mM KP Buffer pH=7.0, 1.5 
mM KCN and 0.1 mM DCPIP. This reaction was followed after the injection of 16 mM 
succinate (SDH activity) and 50 mM CoQ (CII activity) at 600 nm for two minutes. Complex 
III was assessed measuring the reduction of cytochrome c at 550 nm for 2 min at 30°C. Proteins 
were incubated with 50 mM KP buffer pH=7.4, 2 mM NaN3, 1 mg/ml BSA (in EDTA 10 mM 
pH=7.4), 50 mM Cytochrome c (SIGMA #C7752), and 50 mM reduced decylubiquinone 
(DBH2, Sigma #D7911). CIV activity was measured at 550 nm following cytochrome c 
oxidation for two minutes at 37°C. Assay was performed in 90 - 95% reduced cytochrome c 
(1.3 mg/ml, SIGMA #C7752) in 50 mM KP buffer pH=7.0. All enzymatic activities were 
normalized for protein quantification (DC assay kit, Bio-Rad) and for citrate synthase (CS) 
activity. For CS activity measurements, proteins were incubated at 30°C with 75 mM Tris-HCl 
Buffer pH=8.0, 0.1 mM 5,5ʹ - Dithiobis-(2-nitrobenzoic acid) (DTNB) and 0.4 mM Acetyl-
CoA. The reaction was initiated adding 0.5 mM Oxalacetate and followed at 412 nm for two 
minutes. 
To analyse translation of mitochondrially encoded proteins metabolic labelling was performed 
as previously described (Rorbach et al., 2014). Cells were grown as described and, then the 
standard medium was replaced with methionine/cysteine free DMEM (Sigma-Aldrich) 
supplemented with 2 mM l-glutamine, 48 μg/ml cysteine, and 50 μg/ml uridine. The cells were 
incubated for 2 Å~ 10 min in this medium and then transferred to methionine/cysteine-free 
DMEM containing 10% (vol/vol) dialyzed FCS and emetine dihydrochloride (100 μg/ml) to 
inhibit cytosolic translation. Cells were incubated for 10 min before addition of 120 μCi/ml of 
[35S]methionine. Labeling was performed for 60 min, and then the cells were washed twice 
with standard growth medium. Protein samples  (30 μg) were separated on 10-20% SDS–PAGE 
gels, and products were visualized and quantified using a PhosphorImager system with 
ImageQuant software (Molecular Dynamics, GE Healthcare). 
 
Statistics 
Statistical analyses were performed using GraphPad Prism software version XXX. P values 
less than 0.05 according to a two-tailed Student’s t-test were considered significant. 
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Figure 2. Brain MRI and MR Spectroscopy findings of the patient obtained at 2.5 years (A-E, 
K, L) and 7 years of age (F-J, M). Axial T2-weighted (A, F), fluid-attenuated inversion 
recovery (FLAIR) (B, G), diffusion-weighted images (DWI) (C, H), sagittal T2-weighted (D, 
I) and coronal T2-weighted (E, J) images are shown. The initial MRI shows diffuse cerebral 
white matter abnormalities, mainly in the frontal and right parietal lobes (A, B), involving both 
the periventricular and subcortical regions, with central rarefaction (asterisks, B). The 
abnormal cerebral white matter is surrounded by a rim of abnormal solid tissue, with linear 
areas of restricted diffusion (arrows, C). There is swelling and T2-hyperintensities at the level 
of the anterior portions of the corpus callosum and splenium, with preservation of the fibres 
connecting the pericentral cortex (arrow, D). There is a very small area of signal abnormality 
of the cerebellar cortex in the right hemisphere (empty arrow, E). The late MRI reveals 
improvement of the deep white matter changes with absence of restricted diffusion (G, H), and 
thinning of the affected white matter with mild enlargement of the lateral ventricles (asterisks, 
F). There is atrophy of the corpus callosum (arrowheads, I). The cerebellar abnormalities 
slightly worsen (empty arrow, J). MR spectroscopy at 2.5 years of age demonstrate very high 
lactate peaks in the affected white matter (arrow, K) and smaller lactate peaks in the spared, 
normal-appearing white matter (arrow, L). Follow-up MR spectroscopy performed at 7 years 
of age reveals no significant lactate peaks in the affected cerebral white matter (M). 
  
 
Figure 3 - Functional characterisation of NUBPL defective immortalised fibroblasts vs three 
independent controls: the analyses of A) steady-state level of CI (NDUFV1, NDUFS1, 
NDUFS2, NDUFS3, NDUFA9, NDUFB11, NDUFB8), CII (SDHA), CIII (UQCRC2, 
UQCRFS1), CIV (MTCO1, COXIV), CV (ATPA5) and loading control (GAPDH) by WB 
analysis of SDS page from fibroblast lysates; B) 1D BN-PAGE and C) 2D BN- PAGE WB 
study with 1%DDM treated proteins; D) 1D BN-PAGE and E) 2D BN- PAGE study with 1% 
Digitonin treated proteins; F) 35S-methionine labelling for mitochondrial protein translation 
were performed in patient’s and controls immortalised fibroblasts; and, G) Spectrophotometer 
analysis of mitochondrial respiratory chain complex activities in fibroblast lysates. Data in 
figures are given as mean +/- SEM based on at least 3 biological replicates. 
CI= NADH:ubiquinone oxidoreductase; CII= succinate:ubiquinone oxidoreductase ; 





Figure 4 – Stable lentiviral transfection of wild-type NUBPL restored the defective Complex 
I as demonstrated by analysing the A) Steady state levels of NUBPL and CI subunits 
(NDUFS1, NDUFS2, NDUFA9, NDUFB8) by SDS page analysis; B) 1D and C) 2D BN PAGE 
WB of samples treated with 1% DDM and D) 1D BN PAGE of Rieske protein in 1%DDM 
treated samples; E) spectrophotometer analysis of mitochondrial respiratory chain activities; 
F) 35S-methionine labelling for mitochondrial proteins translation. Data in figures are given as 
mean +/- SEM based on at least 3 biological replicates. 
CI= NADH:ubiquinone oxidoreductase; CII= succinate:ubiquinone oxidoreductase ; SDH= 










Table II: mitochondrial respiratory chain activities (μmole/min/g) in muscle homogenate 
  
Supplemental material 
Supplemental Figure 1 - ClustalW alignment of human NUBPL (NP_079428.2) and cytosolic 
human orthologues of cytosolic Fe/S proteins Cfd1/Nbp35 NUBP1 (NP_002475.2). 
The main domains are indicated in yellow, while in green are highlighted the mutations found 








Supplemental Figure 3 – Digitonin treated protein from ACAD9 defective human fibroblast 
cell line and control: A) 1D BN Page showing reduction of Complex I in ACAD9 cell line; 
B) 2D 









Supplemental Figure 5 - 35-S-methionine labelling for mitochondrial proteins translation in 













Supplemental Table 1- List of antibodies 
 
 
 
